Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2021

View Archived Issues

Excitability phenotype screen identifies several targets in human amyotrophic lateral sclerosis

New cannabinoid CB2 receptor agonists discovered at Corbus Pharmaceuticals

Incyte presents new fibroblast growth factor receptor inhibitors

Omeros discovers mannan-binding lectin serine protease 2 inhibitors

Neurocrine Biosciences presents new muscarinic M4 receptor antagonists

New GTPase KRAS G12C mutant inhibitors discovered at Beta Pharma

ETX-0462: a promising global Gram-negative antimicrobial agent

VRP-034: A nephroprotective SMC complex of polymyxin B for Gram-negative infections

PRO-C18L may predict response to liver fibrosis treatment

I-Mab provides updates for its 4-1BB bispecific antibody portfolio

Topline phase II data for VAL-083 in patients with recurrent GBM

FDA provides notice to proceed with phase I study of HDT-301 RNA COVID-19 vaccine

Aileron initiates phase Ib study of ALRN-6924 in advanced NSCLC

Exome study identifies new genetic influences on weight

ALG-010133: a STOPS for chronic hepatitis B treatment

LG Chem reports data from phase II CLUE study of LC-350189 in chronic gout

Ildong announces initiation of phase I study of IDG-16177 in Germany

Discovery and preclinical data presented for VNRX-9945

Phase Ib data for triple combination of SHR-6390 plus pyrotinib and letrozole in mBC

Phase I trial rVSVdeltaG-LASV-GPC vaccine in healthy adults

Universal antiviral vaccine candidate AlloStim studied in phase I/II trial

Phase II trial evaluates bepranemab in mild cognitive impairment or mild Alzheimer's disease

Neoantigen-specific cytotoxic T cells show in vivo efficacy in Ewing sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...